Last Update Time:
12-Mar-2025 16:00:00
ISIN:
INE540L01014
Sector:
Healthcare
Symbol:
ALKEM
Alkem Laboratories Limited
₹4,726.00
₹-51.75
(-1.08%)
▼
Prev. Close
₹4,777.75
Open
₹4,775.00
Close
₹4,749.40
Range
₹4,489.70 - ₹4,962.30
High
₹4,805.90
Low
₹4,696.50
Ind. Close
₹0.00
VWAP
₹4,741.37
The current stock price of Alkem Laboratories Limited is ₹4,726.00, with a target price range between ₹4,489.70 and ₹4,962.30. The stock has experienced a price change of ₹-51.75 (-1.08%), reflecting recent market volatility.
Today's opening price was ₹4,775.00, while the previous close stood at ₹4,777.75.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Alkem Laboratories Limited Price Chart
Alkem Laboratories Limited Pre Open Market Overview: 12-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 4775
- Previous Close Price: 4777.75
- Change: -2.75%
- Total Traded Volume: 217
- Total Buy Quantity: 733
- Total Sell Quantity: 958
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 4,751.80 | 20.00 | 0.00 |
| 4,752.00 | 5.00 | 0.00 |
| 4,755.00 | 2.00 | 0.00 |
| 4,766.00 | 1.00 | 0.00 |
| 4,775.00 | 40.00 | 0.00 |
| 4,777.75 | 0.00 | 4.00 |
| 4,778.00 | 0.00 | 1.00 |
| 4,781.95 | 0.00 | 1.00 |
| 4,788.95 | 0.00 | 1.00 |
| 4,790.00 | 0.00 | 30.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 733
Total Sell Quantity: 958
Shareholding Patterns of Alkem Laboratories Limited
Key Trade Statistics of Alkem Laboratories Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.99 |
| Traded Value (₹ Cr.) | 47.03 |
| Total Market Cap (₹ Cr.) | 56,506.42 |
| Free Float Market Cap (₹ Cr.) | 25,176.67 |
| Impact cost | 0.03 |
| Quantity Traded | 99,185.00 |
| Deliverable Quantity | 56,352.00 |
| % of Quantity to Traded | 56.82 |
| Security VaR | 9.99 |
| Index VaR | N/A |
| VaR Margin | 9.99 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 13.49 |
| Face Value | 2 |
Key Price Statistics of Alkem Laboratories Limited
The 52-week high for Alkem Laboratories Limited was ₹6,439.90, recorded on 13-Sep-2024. On the other hand, the 52-week low stands at ₹4,407.05, with the lowest value recorded on 04-Jun-2024.
The upper band for trading is ₹5,255.50, and the lower band is ₹4,300.00. The price band is No Band%.
The stock's daily volatility stands at 1.59, while the annualized volatility is 30.38. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (13-Sep-2024) | 6,439.90 |
| 52 Week Low (04-Jun-2024) | 4,407.05 |
| Upper Band | 5,255.50 |
| Lower Band | 4,300.00 |
| Price Band (%) | No Band |
| Daily Volatility | 1.59 |
| Annualised Volatility | 30.38 |
| Tick Size | 0.05 |
Key Securities Statistics of Alkem Laboratories Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 23-Dec-2015 |
| Adjusted P/E | 25.88 |
| Symbol P/E | 26 |
| Index | NIFTY MIDCAP 50 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Alkem Laboratories Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Alkem Laboratories Limited
| Subject | Date |
|---|---|
| Press Release | 12-Mar-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 10-Mar-2025 |
| Appointment | 10-Mar-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 10-Mar-2025 |
| Action(s) initiated or orders passed | 01-Mar-2025 |
| Action(s) initiated or orders passed | 01-Mar-2025 |
| Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent | 28-Feb-2025 |
| Appointment | 28-Feb-2025 |
Corporate Actions of Alkem Laboratories Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 2 | Interim Dividend - Rs 37 Per Share | 14-Feb-2025 |
| 2 | Dividend - Rs 5 Per Share | 09-Aug-2024 |
| 2 | Interim Dividend - Rs 35 Per Share | 16-Feb-2024 |
| 2 | Dividend - Rs 10 Per Share | 10-Aug-2023 |
| 2 | Interim Dividend - Rs 15 Per Share & Special Dividend Rs 25 Per Share | 17-Feb-2023 |
| 2 | Dividend - Rs 4 Per Share | 08-Aug-2022 |
| 2 | Interim Dividend - Rs 30 Per Sh | 10-Feb-2022 |
| 2 | Dividend - Rs 5 Per Share | 09-Aug-2021 |
| 2 | Interim Dividend - Rs 25 Per Share | 11-Feb-2021 |
| 2 | Annual General Meeting/Dividend - Rs 3 Per Share | 10-Aug-2020 |
| 2 | Interim Dividend - Rs 22 Per Share | 13-Feb-2020 |
| 2 | Annual General Meeting/Dividend - Rs 8 Per Share | 19-Aug-2019 |
| 2 | Interim Dividend - Rs 8 Per Share | 15-Feb-2019 |
| 2 | Annual General Meeting/Dividend- Rs 7 Per Share | 23-Aug-2018 |
| 2 | Interim Dividend - Rs 6 Per Share (Purpose Revised) | 16-Feb-2018 |
| 2 | Annual General Meeting/ Dividend -Rs 9/- Per Share | 31-Aug-2017 |
| 2 | Interim Dividend Rs 6/- Per Share | 23-Nov-2016 |
| 2 | Interim Dividend -Rs 9.70/- Per Share | 18-Mar-2016 |
Board Meetings of Alkem Laboratories Limited
Financial Results of Alkem Laboratories Limited
Company Directory of Alkem Laboratories Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.alkemlabs.com | Registered Office | Alkem House, Senapati Bapat Marg, Lower Parel, | MUMBAI |
| www.alkemlabs.com | Transfer Agent | C-13, Pannalal Silk Mills Compound L.B.S Marg Bhandup (West) | MUMBAI |
Insider Trading of Alkem Laboratories Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Deepak Kumar Singh | 90235579 | Sell |
| 7(2) | Mritunjay Kumar Singh | 10691874 | Buy |
| 7(2) | Mritunjay Kumar Singh | 5188662 | Buy |
| 7(2) | Dhananjay and Madhurima Singh Trust | 3438750 | Buy |
| 7(2) | Dhananjay and Madhurima Singh Trust | 6591741 | Buy |
| 7(2) | Deepak Kumar Singh | 6982333 | Sell |
| 7(2) | Deepak Kumar Singh | 6874627 | Sell |
| 7(2) | Deepak Kumar Singh | 17179131 | Sell |
| 7(2) | Jayanti Sinha | 0 | Sell |
| 7(2) | Deepak Kumar Singh | 17862762 | Sell |
| 7(2) | Balmiki Prasad Singh | 0 | Buy |
| 7(2) | Satish Kumar Singh | 0 | Buy |
| 7(2) | Deepak Kumar Singh | 15696056 | Sell |
| 7(2) | Deepak Kumar Singh | 15672126 | Sell |
| 7(2) | Deepak Kumar Singh | 18505344 | Sell |
| 7(2) | Alok Kumar | 0 | Buy |
| 7(2) | Mr. Ashok kumar | 0 | Buy |
| 7(2) | Balmiki Prasad Singh | 0 | Buy |
| 7(2) | Satish Kumar Singh | 0 | Buy |
| 7(2) | Madhurima Singh | 0 | Sell |
Annual Reports of Alkem Laboratories Limited
Investor Complaints of Alkem Laboratories Limited
Event Calendar of Alkem Laboratories Limited
| Purpose | Details |
|---|---|
| Results | Inter alia , to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2015. |
| Dividend | Inter alia to consider and approve second interim dividend for the Financial Year 2015-16. |
| Results | To consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2016. |
| Results | inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2016. |
| Results/Dividend | inter alia: (i) to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016; and (ii) to consider and approve Interim Dividend for the Financial Year 2016-2017. |
| Results | inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016. |
| Results/Dividend | inter alia, (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended March 31, 2017; and (ii) to consider and recommend Final Dividend, if any, for the Financial Year ended March 31, 2017. |
| Results | inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended June 30, 2017. |
| Results | Inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. |
| Results/Dividend | , inter alia: (i) to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017; and (ii) to consider and approve Interim Dividend for the Financial Year 2017-2018. |
| Financial Results/Dividend | Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Wednesday, 30th May, 2018, inter alia, (i) to consider and approve the Standalone and Consolidated Audited Financial Results of the Company for the quarter and financial year ended 31st March, 2018; and(ii) to consider and recommend Final Dividend, if any, for the Financial Year ended 31st March, 2018.Kindly take note of the same. |
| Financial Results | Notice is hereby given to the Stock Exchanges under Regulation 29 read with Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 that a meeting of the Board of Directors of the Company is scheduled to be held on Friday, 10th August, 2018, inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter ended 30th June, 2018. |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results/Dividend | To consider and approve the financial results for the quarter and nine months ended December 31, 2018 and interim dividend for FY 2018-19. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2019 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2019 and dividend. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results/Dividend | To consider and approve the (i) financial results for the period ended December 31, 2020; and (ii) Interim Dividend for the Financial Year 2020-2021. |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2021 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2021 and dividend |
| Financial results | Alkem Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Aug-2022 to consider financial statements for the period ended June 2022 |
| Financial results | Alkem Laboratories Limited has informed the Exchange about Board Meeting to be held on 11-Nov-2022 to consider financial statements for the period ended September 2022 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2022 and interim dividend for the financial year 2022-2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2023 and dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2023 and dividend |
| Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2024 and final dividend |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended December 31, 2024 and dividend |
Share Transfers of Alkem Laboratories Limited
Voting Results of Alkem Laboratories Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 03-OCT-2024 | Postal Ballot | Appointment of Mr. Rajeev Kher (DIN: 01192524) as an Independent Director of the Company for a period of five consecutive years w.e.f. 09th August, 2024 upto 08th August, 2029. |
| 30-AUG-2024 | AGM | To receive, consider and adopt:na.tthe Audited Standalone Financial Statements of the Company for financial year ended 31st March, 2024 and the Reports of the Board of Directors and Auditors thereon; andnb.tthe Audited Consolidated Financial Statements of the Company for financial year ended 31st March, 2024 and the Reports of Auditors thereon. |
| 30-AUG-2024 | AGM | Ratification of payment of fees to Mr. Suresh D. Shenoy, Cost Accountant (Membership No. 8318), as Cost Auditor of the Company. |
| 30-AUG-2024 | AGM | Re-appointment of Mr. Narendra Kumar Aneja (DIN: 00124302) as an Independent Director of the Company for a term of 5 (five) consecutive years with effect from 16th March, 2025 upto 15th March, 2030. |
| 30-AUG-2024 | AGM | Re-appointment of Mr. Sarvesh Singh (DIN: 01278229) as an Executive Director of the Company for a term of 5 (five) consecutive years with effect from 11th November, 2024 upto 10th November, 2029. |
| 30-AUG-2024 | AGM | Re-appointment of Mr. Basudeo N. Singh (DIN: 00760310) as an Executive Chairman of the Company for a term of 3 (three) consecutive years with effect from 01st April, 2025 upto 31st March, 2028. |
| 30-AUG-2024 | AGM | Appointment of M/s. Deloitte Haskins & Sells LLP, Chartered Accountants (Firm Registration No. 117366W/W-100018) as Statutory Auditors of the Company and to fix their fees. |
| 30-AUG-2024 | AGM | Appointment of Mr. Sarvesh Singh (DIN: 01278229), who retires by rotation and being eligible, offers himself for re-appointment. |
| 30-AUG-2024 | AGM | Appointment of Mrs. Madhurima Singh (DIN: 09137323), who retires by rotation and being eligible, offers herself for re-appointment. |
| 30-AUG-2024 | AGM | Confirm the payment of interim dividend and to declare final dividend on equity shares for financial year ended 31st March, 2024. |
| 05-APR-2024 | Postal Ballot | Reclassification of certain members of 'Promoter Group' to 'Public' Category. |
| 06-JAN-2024 | Postal Ballot | Amendment to the Objects of Memorandum of Association of the Company |
| 07-OCT-2023 | Postal Ballot | Appointment of Mr. Aniruddha Singh to hold office of profit as AVP ￢ﾀﾓ CMD Office of the Company. |
| 25-AUG-2023 | AGM | Receive, consider and adopt:nna) the Audited Standalone Financial Statements of the Company for the financial year ended 31st March, 2023 and the Reports of the Board of Directors and Auditors thereon; andnnb) the Audited Consolidated Financial Statements of the Company for the financial year ended 31st March, 2023 and the Reports of Auditors thereon. |
| 25-AUG-2023 | AGM | Ratification for payment of remuneration to Mr. Suresh D. Shenoy, Cost Accountant (Membership No. 8318), as Cost Auditor of the Company. |
| 25-AUG-2023 | AGM | Approval for alteration to the Articles of Association of the Company. |
| 25-AUG-2023 | AGM | Appointment of Mr. Sandeep Singh (DIN: 01277984), who retires by rotation and being eligible, offers himself for re-appointment. |
| 25-AUG-2023 | AGM | Appointment of Mr. Mritunjay Kumar Singh (DIN: 00881412), who retires by rotation and being eligible, offers himself for re-appointment. |
| 25-AUG-2023 | AGM | Confirm the payment of interim dividend and to declare final dividend on equity shares for the financial year ended 31st March, 2023. |
| 05-JAN-2023 | Postal Ballot | Re-appointment of Mr. Mritunjay Kumar Singh (DIN: 00881412) as an Executive Director of the Company for a period of five (5) consecutive years w.e.f. 01st January, 2023 to 31st December,2027 |
FAQs on Alkem Laboratories Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.